Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 30, 2019 - Issue 2
Submit an article Journal homepage
350
Views
8
CrossRef citations to date
0
Altmetric
Psoriasis and dermatitis

Biologic treatment of recalcitrant pediatric psoriasis: a case series from a tertiary medical center

Ayelet OllechDepartment of Dermatology, Northwestern University Chicago, IL, USA; Correspondence[email protected]
,
Alex ZvulunovDepartment of Dermatology, Soroka Medical center, Be’er Sheva, Israel; ;Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel;
,
Lev PavlovskyDepartment of Dermatology, Rabin medical center Petach Tikva, Israel;
,
Emmilia HodakDepartment of Dermatology, Rabin medical center Petach Tikva, Israel; ;Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;
&
Dan Ben-AmitaiSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ;Pediatric Dermatology Unit, Schneider Children’s Hospital, Israel
Pages 152-155 | Received 22 Apr 2018, Accepted 28 Apr 2018, Published online: 04 Jun 2018

References

  • Tollefson MM, Crowson CS, McEvoy MT. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62:979–987.
  • Burden E, Burden-Teh KS, Thomas S, et al. The epidemiology of childhood psoriasis: a scoping review. Br J Dermatol. 2016;174:1242–1257.
  • Augustin M, Glaeske G, Radtke MA. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162:633–636.
  • Osier E, Wang AS, Tollefson MM. Pediatric Psoriasis Comorbidity Screening Guidelines. JAMA Dermatol. 2017;153:698–704.
  • Kimball AB, Wu EQ, Guerin A. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67:651–657.
  • Ahn CS, Dothard EH, Garner ML. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2015;73:420–428.
  • Shah KN. Diagnosis and treatment of pediatric psoriasis: current and future. Am J Clin Dermatol. 2013;14:195–213.
  • Marqueling AL, Cordoro KM. Systemic treatments for severe pediatric psoriasis. A Practical Approach Dermatol Clin. 2013;31:267–288.
  • FDA.gov [Internet]. 2018 [cited 2018 March 7]. Available from: https://www.fda.gov
  • EMA.europa.eu [Internet]. 2018 [cited 2018 March 7]. Available from: http://www.ema.europa.eu
  • Garber C, Creighton-Smith M, Sorensen EP. Systemic treatment of recalcitrant pediatric psoriasis: a case series and literature review. J Drugs Dermatol. 2015;14:881–886.
  • Klufas DM, Wald JM, Strober BE. Treatment of moderate to severe pediatric psoriasis: a retrospective case series. Pediatr Dermatol. 2016;33:142–149.
  • Paller AS, Siegfried EC, Langley RG. Etanercept Pediatric Psoriasis Study Group. N Engl J Med. 2008;358:241–251.
  • Paller AS, Siegfried EC, Eichenfield LF. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63:762–768.
  • Paller AS. Siegfried long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;73:594–603.
  • Pap K. Adalimumab long-term safety/efficacy results for pediatric patients with chronic plaque psoriasis from a phase 3, randomized study. J Am Acad Dermatol. 2016;74:AB209.
  • Landells I, Marano C, Hsu MC. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73:594–603.
  • Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol. 2004;21:87–88.
  • Farnsworth NN1, George SJ, Hsu S. Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol Online J. 2005;11:11.
  • Bellodi Schmidt F, Shah KN. Biologic response modifiers and pediatric psoriasis. Pediatr Dermatol. 2015;32:303–320.
  • Diak P, Siegel J, La grenade L. Tumour necrosis factor a blockers and malignancy in children: forty-eight cases reported to the food and drug administration. Arthritis Rheum. 2010;62:2514–2527.
  • Leonardi C, Strober B, Gottlieb AB. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010;9:928–937.
  • Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–115.
  • Papp KA, Langley RG, Lebwohl M. Efficacy and safety of Ustekinumab, a new human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–1684.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.